The expression of the oestrogen receptor (OR), progesterone receptor (PR) and Her2/neu receptors (HER2+), which are routinely measured by immunohistochemistry (IHC), and are frequently used as practical, surrogate markers of the breast cancer biologic subtype [6]. This evidence concerns the gene ERBB2 and breast carcinoma.